Tocagen (TOCA) Report Continuation of Toca 5 Pivotal Phase 3 Clinical Trial Without Modification at Planned First Interim Analysis
Tocagen Inc. (NASDAQ: TOCA) today announced the Toca 5 pivotal Phase 3 trial continues without modification following a planned first ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)